MRI contrast agent: Difference between revisions
CSV import |
CSV import |
||
| Line 34: | Line 34: | ||
[[Category:Radiology]] | [[Category:Radiology]] | ||
{{medicine-stub}} | {{medicine-stub}} | ||
== MRI contrast agent == | |||
<gallery> | |||
File:Bluthirnschranke_nach_Infarkt_nativ_und_KM.png | |||
</gallery> | |||
Latest revision as of 22:08, 16 February 2025
MRI Contrast Agent
An MRI contrast agent is a type of chemical substance used in MRI procedures to enhance the visibility of internal body structures. These agents are typically injected into the patient's bloodstream and work by altering the magnetic field within the body, thereby improving the contrast and detail of the MRI images.
Types of MRI Contrast Agents[edit]
There are two main types of MRI contrast agents: Gadolinium-based agents and Iron Oxide-based agents.
Gadolinium-Based Agents[edit]
Gadolinium-based agents are the most commonly used MRI contrast agents. Gadolinium is a rare earth metal that has unique magnetic properties. When injected into the body, it interacts with the magnetic field of the MRI scanner to enhance the contrast of the images. There are several different types of gadolinium-based agents, including linear and macrocyclic agents.
Iron Oxide-Based Agents[edit]
Iron Oxide-based agents, also known as superparamagnetic iron oxide nanoparticles (SPIONs), are another type of MRI contrast agent. These agents are less commonly used than gadolinium-based agents, but they can provide superior contrast in certain types of imaging, particularly for imaging of the liver and spleen.
Safety and Side Effects[edit]
While MRI contrast agents are generally considered safe, they can cause side effects in some patients. These can range from mild reactions, such as nausea and headaches, to more serious conditions, such as nephrogenic systemic fibrosis (NSF), a rare but serious disease that can occur in patients with severe kidney disease who are given gadolinium-based agents.
Regulation and Approval[edit]
MRI contrast agents are regulated as drugs and must be approved by regulatory bodies such as the FDA in the United States and the EMA in Europe. These agencies review the safety and efficacy of the agents before they can be used in patients.
See Also[edit]
